Advanced search
Publication Cover
Pharmacogenomics Volume 13, 2012 - Issue 2
Submit an article Journal homepage
547
Views
0
CrossRef citations to date
0
Altmetric
Research Article

Pharmacogenomics of Cisplatin-Based Chemotherapy in Ovarian Cancer Patients of Different Ethnic Origins

Andrey Khrunin1 Department of Molecular Bases of Human Genetics, Institute of Molecular Genetics, Russian Academy of Sciences, Moscow, RussiaCorrespondence[email protected]
View further author information
,
Feodosia Ivanova2 Yakutsk Republic Cancer Clinic, Yakutsk, RussiaView further author information
,
Alexey Moisseev3 Department of Chemotherapy, NN Blokhin Cancer Research Centre, Russian Academy of Medical Sciences, Moscow, RussiaView further author information
,
Denis Khokhrin1 Department of Molecular Bases of Human Genetics, Institute of Molecular Genetics, Russian Academy of Sciences, Moscow, RussiaView further author information
,
Yuliya Sleptsova1 Department of Molecular Bases of Human Genetics, Institute of Molecular Genetics, Russian Academy of Sciences, Moscow, Russia;4 The Russian State Medical University, Moscow, RussiaView further author information
,
Vera Gorbunova3 Department of Chemotherapy, NN Blokhin Cancer Research Centre, Russian Academy of Medical Sciences, Moscow, RussiaView further author information
&
Svetlana Limborska1 Department of Molecular Bases of Human Genetics, Institute of Molecular Genetics, Russian Academy of Sciences, Moscow, RussiaView further author information
 show all
Pages 171-178 | Published online: 18 Jan 2012

References

  • O‘Donnell PH , DolanME. Cancer pharmacoethnicity: ethnic differences in susceptibility to the effects of chemotherapy. Clin. Cancer Res.15(15) , 4806–4814 (2009).
  • Morris AM , RhoadsKF, StainSC, BirkmeyerJD. Understanding racial disparities in cancer treatment and outcomes. J. Am. Coll. Surg.211(1) , 105–113 (2010).
  • Tishkoff SA , VerrelliBC. Patterns of human genetic diversity: implications for human evolutionary history and disease. Annu. Rev. Genomic Hum. Genet.4 , 293–340 (2003).
  • Kidd KK , PakstisAJ, SpeedWC, KiddJR. Understanding human DNA sequence variation. J. Hered.95(5) , 406–420 (2004).
  • Auton A , BrycK, BoykoAR et al. Global distribution of genomic diversity underscores rich complex history of continental human populations. Genome Res. 19(5) , 795–803 (2009).
  • Coop G , PickrellJK, NovembreJ et al. The role of geography in human adaptation. PLoS Genet. 5(6) , e1000500 (2009).
  • Phan VH , MooreMM, McLachlanAJ, Piquette-MillerM, XuH, ClarkeSJ. Ethnic differences in drug metabolism and toxicity from chemotherapy. Expert Opin. Drug Metab. Toxicol.5(3) , 243–257 (2009).
  • Muggia F . Platinum compounds 30 years after the introduction of cisplatin: implications for the treatment of ovarian cancer. Gynecol. Oncol.112(1) , 275–281 (2009).
  • Shimoyama S . Pharmacogenetics of fluoropyrimidine and cisplatin. A future application to gastric cancer treatment. J. Gastroenterol. Hepatol.24(6) , 970–981 (2009).
  • Gandara DR , KawaguchiT, CrowleyJ et al. Japanese-US common-arm analysis of paclitaxel plus carboplatin in advanced non-small-cell lung cancer: a model for assessing population-related pharmacogenomics. J. Clin. Oncol. 279(21) , 3540–3546 (2009).
  • Khrunin AV , MoisseevA, GorbunovaV, LimborskaS. Genetic polymorphisms and the efficacy and toxicity of cisplatin-based chemotherapy in ovarian cancer patients. Pharmacogenomics J.10(1) , 54–61 (2010).
  • Milligan BG . Total DNA isolation. In: Molecular Genetic Analysis of Populations. Hoelzel AR (Ed.). Oxford University Press, Oxford, UK, 29–60 (1998).
  • Coles BF , MorelF, RauchC et al. Effect of polymorphism in the human glutathione S-transferase A1 promoter on hepatic GSTA1 and GSTA2 expression. Pharmacogenetics 11(8) , 663–669 (2001).
  • Khrunin AV , KhokhrinDV, LimborskaSA. Glutathione-S-transferase gene polymorphism in Russian populations of European part of Russia. Genetika44(10) , 1429–1434 (2008).
  • Loktionov A , WatsonMA, GunterM, StebbingsWS, SpeakmanCT, BinghamSA. Glutathione-S-transferase gene polymorphisms in colorectal cancer patients: interaction between GSTM1 and GSTM3 allele variants as a risk-modulating factor. Carcinogenesis22(7) , 1053–1060 (2001).
  • Tetlow N , RobinsonA, MantleT, BoardP. Polymorphism of human mu class glutathione transferases. Pharmacogenetics14(6) , 359–368 (2004).
  • Ishii T , MatsuseT, TeramotoS et al. Glutathione S-transferase P1 (GSTP1) polymorphism in patients with chronic obstructive pulmonary disease. Thorax 54(8) , 693–696 (1999).
  • Saarikoski ST , VohoA, ReinikainenM et al. Combined effect of polymorphic gst genes on individual susceptibility to lung cancer. Int. J. Cancer 77(7) , 516–521 (1998).
  • Zhou W , GurubhagavatulaS, LiuG et al. Excision repair cross-complementation group 1 polymorphism predicts overall survival in advanced non-small cell lung cancer patients treated with platinum-based chemotherapy. Clin. Cancer Res. 10(15) , 4939–4943 (2004).
  • Matullo G , PalliD, PelusoM et al. XRCC1, XRCC3, XPD gene polymorphisms, smoking and (32)P-DNA adducts in a sample of healthy subjects. Carcinogenesis 22(9) , 1437–1445 (2001).
  • Tuimala J , SzekelyG, GundyS, HirvonenA, NorppaH. Genetic polymorphisms of DNA repair and xenobiotic-metabolizing enzymes: role in mutagen sensitivity. Carcinogenesis23(6) , 1003–1008 (2002).
  • Seedhouse C , BaintonR, LewisM, HardingA, RussellN, Das-GuptaE. The genotype distribution of the XRCC1 gene indicates a role for base excision repair in the development of therapy-related acute myeloblastic leukemia. Blood.100(10) , 3761–3766 (2002).
  • Sjalander A , BirganderR, KivelaA, BeckmanG (1995) p53 polymorphisms and haplotypes in different ethnic groups. Hum. Hered.45(3) , 144–149 (1995).
  • Fritsche E , GaryS. Pittman, Douglas A. Bell. Localization, sequence analysis, and ethnic distribution of a 96-bp insertion in the promoter of the human CYP2E1 gene. Mutat. Res.432(1–2) , 1–5 (2000).
  • Wong NA , RaeF, SimpsonKJ, MurrayGD, HarrisonDJ. Genetic polymorphisms of cytochrome p4502E1 and susceptibility to alcoholic liver disease and hepatocellular carcinoma in a white population: a study and literature review, including meta-analysis. Mol. Pathol.53(2) , 88–93 (2000).
  • Ardizzoni A , BoniL, TiseoM et al.: Cisplatin- versus carboplatin-based chemotherapy in first-line treatment of advanced non-small-cell lung cancer: an individual patient data meta-analysis.J. Natl Cancer Inst.99(11) , 847–57 (2007).
  • Boulikas T , VougioukaM. Cisplatin and platinum drugs at the molecular level. Oncol. Rep.10(6) , 1663–1682 (2003).
  • Ishimoto TM , Ali-OsmanF. Allelic variants of the human glutathione S-transferase P1 gene confer differential cytoprotection against anticancer agents in Escherichia coli. Pharmacogenetics12(7) , 543–553 (2002).
  • Peklak-Scott C , SmithermanPK, TownsendAJ, MorrowCS. Role of glutathione S-transferase P1-1 in the cellular detoxification of cisplatin. Mol. Cancer Ther.7(10) , 3247–3255 (2008).
  • Yu JJ , LeeKB, MuC et al. Comparison of two human ovarian carcinoma cell lines (A2780/CP70 and MCAS) that are equally resistant to platinum, but differ at codon 118 of the ERCC1 gene. Int. J. Oncol. 16(3) , 555–560 (2000).
  • Chen P , WienckeJ, AldapeK et al. Association of an ERCC1 polymorphism with adult-onset glioma. Cancer Epidemiol. Biomarkers. Prev. 9(8) , 843–847 (2000).
  • Au WW , SalamaSA, Sierra-TorresSH. Functional characterization of polymorphisms in DNA repair genes using cytogenetic challenge assays. Environ. Health. Perspect.111(15) , 1843–1850 (2003).
  • Wolfe KJ , WickliffeJK, HillCE, PaoliniM, AmmenheuserMM, Abdel-RahmanSZ. Single nucleotide polymorphisms of the DNA repair gene XPD/ERCC2 alter mRNA expression. Pharmacogenet. Genomics.17(11) , 897–905 (2007).
  • Jung Y , LippardSJ. Direct cellular responses to platinum-induced DNA damage. Chem. Rev.107(5) , 1387–1407 (2007).
  • Siddik ZH . Cisplatin: mode of cytotoxic action and molecular basis of resistance. Oncogene22(47) , 7265–7279 (2003).
  • Sullivan A , SyedN, GascoM et al. Polymorphism in wild-type p53 modulates response to chemotherapy in vitro and in vivo. Oncogene 23(19) , 3328–3337 (2004).
  • Boige V , MendiboureJ, PignonJP et al. Pharmacogenetic assessment of toxicity and outcome in patients with metastatic colorectal cancer treated with LV5FU2, FOLFOX, and FOLFIRI: FFCD 2000–2005. J. Clin. Oncol. 28(15) , 2556–2564 (2010).
  • Kweekel DM , GelderblomH, AntoniniNF et al. Glutathione-S-transferase pi (GSTP1) codon 105 polymorphism is not associated with oxaliplatin efficacy or toxicity in advanced colorectal cancer patients. Eur. J. Cancer 45(4) , 572–578 (2009).
  • Huang MY , HuangML, ChenMJ et al. Multiple genetic polymorphisms in the prediction of clinical outcome of metastatic colorectal cancer patients treated with first-line FOLFOX-4 chemotherapy. Pharmacogenet. Genomics 21(1) , 18–25 (2011).
  • Ryu JS , HongYC, HanHS et al. Association between polymorphisms of ERCC1 and XPD and survival in non-small-cell lung cancer patients treated with cisplatin combination chemotherapy. Lung Cancer 44(3) , 311–316 (2004).
  • Zhou C , RenS, ZhouS et al. Predictive effects of ERCC1 and XRCC3 SNP on efficacy of platinum-based chemotherapy in advanced NSCLC patients. Jpn J. Clin. Oncol. 40(10) , 954–960 (2010).
  • Tibaldi C , GiovannettiE, VasileE S et al. Correlation of CDA, ERCC1, and XPD polymorphisms with response and survival in gemcitabine/cisplatin-treated advanced non-small cell lung cancer patients. Clin. Cancer. Res.14(6) , 1797–1803 (2008).
  • Kim HS , KimMK, ChungHH et al. Genetic polymorphisms affecting clinical outcomes in epithelial ovarian cancer patients treated with taxanes and platinum compounds: a Korean population-based study. Gynecol. Oncol. 113(2) , 264–269 (2009).
  • Smith S , SuD, Rigault de la Longrais IA et al.ERCC1 genotype and phenotype in epithelial ovarian cancer identify patients likely to benefit from paclitaxel treatment in addition to platinum-based therapy. J. Clin. Oncol.25(33) , 5172–5179 (2007).
  • Nagle CM , Chenevix-TrenchG, SpurdleAB, WebbPM. The role of glutathione-S-transferase polymorphisms in ovarian cancer survival. Eur. J. Cancer43(2) , 283–290 (2007).
  • Lee JM , WuMT, LeeYC et al. Association of GSTP1 polymorphism and survival for esophageal cancer. Clin. Cancer. Res. 11(13) , 4749–4753 (2005).
  • Marsh S , PaulJ, KingCR, GiffordG, McLeodHL, BrownR. Pharmacogenetic assessment of toxicity and outcome after platinum plus taxane chemotherapy in ovarian cancer: the Scottish Randomised Trial in Ovarian Cancer. J. Clin. Oncol.25(29) , 4528–4535 (2007).
  • Kim JG , SohnSK, ChaeYS et al. TP53 codon 72 polymorphism associated with prognosis in patients with advanced gastric cancer treated with paclitaxel and cisplatin. Cancer Chemother. Pharmacol. 64(2) , 355–360 (2009).
  • Gadducci A , Di Cristofano C, Zavaglia M et al.P53 gene status in patients with advanced serous epithelial ovarian cancer in relation to response to paclitaxel- plus platinum-based chemotherapy and long-term clinical outcome. Anticancer Res.26(1B) , 687–693 (2006).
  • McIlwain CC , TownsendDM, TewKD. Glutathione S-transferase polymorphisms: cancer incidence and therapy. Oncogene25(11) , 1639–1648 (2006).
  • Liu H , BaligaM, BaligaR. Effect of cytochrome P450 2E1 inhibitors on cisplatin-induced cytotoxicity to renal proximal tubular epithelial cells. Anticancer Res.22(2A) , 863–868 (2002).
  • Liu H , BaligaR. Cytochrome P450 2E1 null mice provide novel protection against cisplatin-induced nephrotoxicity and apoptosis. Kidney Int.63(5) , 1687–1696 (2003).
  • Lu Y , CederbaumAI. Cisplatin-induced hepatotoxicity is enhanced by elevated expression of cytochrome P450 2E1. Toxicol. Sci.89(2) , 515–523 (2006).
  • Uchimoto T , ItogaS, NezuM, SunagaM, TomonagaT, NomuraF. Role of the genetic polymorphisms in the 5´-flanking region for transcriptional regulation of the human CYP2E1 gene. Alcohol. Clin. Exp. Res.31(1 Suppl.) , S36–S42 (2007).

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.